PL2569009T3 - Chimery ospa i ich zastosowanie do szczepień - Google Patents

Chimery ospa i ich zastosowanie do szczepień

Info

Publication number
PL2569009T3
PL2569009T3 PL11722243T PL11722243T PL2569009T3 PL 2569009 T3 PL2569009 T3 PL 2569009T3 PL 11722243 T PL11722243 T PL 11722243T PL 11722243 T PL11722243 T PL 11722243T PL 2569009 T3 PL2569009 T3 PL 2569009T3
Authority
PL
Poland
Prior art keywords
vaccines
ospa chimeras
ospa
chimeras
Prior art date
Application number
PL11722243T
Other languages
English (en)
Inventor
Brian A. Crowe
Ian Livey
Maria O'rourke
Michael Schwendinger
Original Assignee
Baxalta Incorporated
Baxalta GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta Incorporated, Baxalta GmbH filed Critical Baxalta Incorporated
Publication of PL2569009T3 publication Critical patent/PL2569009T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/20—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Spirochaetales (O), e.g. Treponema, Leptospira
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PL11722243T 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie do szczepień PL2569009T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33490110P 2010-05-14 2010-05-14
PCT/US2011/036525 WO2011143617A1 (en) 2010-05-14 2011-05-13 Chimeric ospa genes, proteins, and methods of use thereof
EP11722243.0A EP2569009B1 (en) 2010-05-14 2011-05-13 Ospa chimeras and use thereof in vaccines

Publications (1)

Publication Number Publication Date
PL2569009T3 true PL2569009T3 (pl) 2020-06-15

Family

ID=44121257

Family Applications (2)

Application Number Title Priority Date Filing Date
PL11720967T PL2569008T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie w szczepionkach
PL11722243T PL2569009T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie do szczepień

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL11720967T PL2569008T3 (pl) 2010-05-14 2011-05-13 Chimery ospa i ich zastosowanie w szczepionkach

Country Status (13)

Country Link
US (6) US8623376B2 (pl)
EP (4) EP3705133B1 (pl)
JP (6) JP6227407B2 (pl)
KR (7) KR102130584B1 (pl)
CN (3) CN107641151B (pl)
AU (2) AU2011252850B2 (pl)
BR (2) BR112012027315B1 (pl)
CA (2) CA2798331C (pl)
MX (3) MX348113B (pl)
PL (2) PL2569008T3 (pl)
RU (2) RU2636455C2 (pl)
SI (2) SI2569008T1 (pl)
WO (2) WO2011143623A1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107641151B (zh) * 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
US20120124496A1 (en) 2010-10-20 2012-05-17 Mark Rose Geographic volume analytics apparatuses, methods and systems
US10438176B2 (en) 2011-07-17 2019-10-08 Visa International Service Association Multiple merchant payment processor platform apparatuses, methods and systems
US10318941B2 (en) 2011-12-13 2019-06-11 Visa International Service Association Payment platform interface widget generation apparatuses, methods and systems
WO2013090611A2 (en) * 2011-12-13 2013-06-20 Visa International Service Association Dynamic widget generator apparatuses, methods and systems
US8986704B2 (en) * 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
RU2015106742A (ru) 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения
PL223175B1 (pl) 2012-10-22 2016-10-31 Inst Chemii Bioorganicznej Polskiej Akademii Nauk Szczepionka przeciw boreliozie, konstrukt genetyczny, rekombinowane białko, sposób otrzymywania konstruktu genetycznego, sposób otrzymywania szczepionki, sposób otrzymywania rekombinowanych białek, zastosowanie rekombinowanych białek do wytwarzania szczepionki przeciwko boreliozie
BR112015023500B1 (pt) * 2013-03-15 2021-01-12 The Regents Of The University Of California composição farmacêutica
WO2015041710A1 (en) * 2013-09-23 2015-03-26 Ventria Bioscience, Inc. Ospa fusion protein for vaccination against lyme disease
MX369195B (es) * 2014-01-09 2019-10-31 Valneva Austria Gmbh Fragmentos mutantes de ospa y métodos y usos relacionados con estos.
CZ2014320A3 (cs) * 2014-05-09 2015-11-18 VÝZKUMNÝ ÚSTAV VETERINÁRNÍHO LÉKAŘSTVÍ, v.v.i. Polyepitopový antigen, vakcinační konstrukt a vakcína pro prevenci lymeské boreliózy
CA2958018A1 (en) 2014-08-11 2016-02-18 University Of Massachusetts Anti-ospa antibodies and methods of use
US11216468B2 (en) 2015-02-08 2022-01-04 Visa International Service Association Converged merchant processing apparatuses, methods and systems
DK3509337T3 (da) * 2015-08-14 2021-06-28 Ericsson Telefon Ab L M Knude og fremgangsmåde til styring af en Packet Data Network-forbindelse
JP2020500033A (ja) * 2016-11-07 2020-01-09 ザ ウィスター インスティテュート オブ アナトミー アンド バイオロジー ライム病に対する使用のためのｄｎａ抗体構築物
ES2957939T3 (es) * 2017-04-13 2024-01-30 Valneva Austria Gmbh Polipéptidos de OspA multivalentes y métodos y usos relacionados con los mismos
JP7614842B2 (ja) 2018-04-03 2025-01-16 サノフイ 抗原性エプスタインバーウイルスポリペプチド
KR20210018206A (ko) 2018-04-03 2021-02-17 사노피 항원성 호흡기 세포융합 바이러스 폴리펩타이드
JP2021519599A (ja) * 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ 抗原性ｏｓｐａポリペプチド
JP2021519596A (ja) 2018-04-03 2021-08-12 サノフイＳａｎｏｆｉ フェリチンタンパク質
CN110483624B (zh) * 2019-08-22 2021-02-09 中国疾病预防控制中心传染病预防控制所 伽氏疏螺旋体OspA蛋白C端肽段及其应用
CN111196842A (zh) * 2020-01-09 2020-05-26 济南大学 一种外膜转运通道蛋白的非跨膜结构域的表达纯化方法
US20240026412A1 (en) 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
CN115698044A (zh) * 2020-04-09 2023-02-03 瓦尔尼瓦奥地利有限责任公司 用于医学用途的包含三种OspA融合蛋白的组合物
US12228578B2 (en) 2020-12-17 2025-02-18 Idexx Laboratories, Inc. Rocky mountain spotted fever detection and treatment
EP4351777A4 (en) * 2021-06-07 2025-04-16 The University of Massachusetts Apparatus and method for the continuous production of RNA
AU2023232562A1 (en) 2022-03-08 2024-09-05 Equashield Medical Ltd Fluid transfer station in a robotic pharmaceutical preparation system
WO2025015077A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and borrelia outer surface protein a and c antigens
WO2025015042A1 (en) 2023-07-10 2025-01-16 Dynavax Technologies Corporation Lyme disease vaccines comprising an adjuvant and a borrelia outer surface protein a antigen

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK590288D0 (da) 1988-10-24 1988-10-24 Symbicom Ab Kemiske forbindelser
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
SE8405493D0 (sv) 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US4877612A (en) 1985-05-20 1989-10-31 Frank M. Berger Immunological adjuvant and process for preparing the same, pharmaceutical compositions, and process
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
EP0231039B1 (en) 1986-01-14 1992-01-08 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Process for preparing immunological complexes and pharmaceutical composition containing these complexes
US4806352A (en) 1986-04-15 1989-02-21 Ribi Immunochem Research Inc. Immunological lipid emulsion adjuvant
US4830885A (en) 1987-06-08 1989-05-16 Allied-Signal Inc. Chlorine-resistant semipermeable membranes
US5777095A (en) 1988-10-24 1998-07-07 Symbicom Aktiebolag Osp A and B Sequence of Borrelia burgdonferi strains ACA1 and IP90
US7094391B1 (en) 1988-10-24 2006-08-22 The University Of Texas System Compositions and methods for administering Borrelia burgdorferi antigens
US6143872A (en) * 1988-10-24 2000-11-07 Symbicom Aktiebolag Borrelia burdorferi Osp A and B proteins and immunogenic peptides
JP2989002B2 (ja) 1988-12-22 1999-12-13 キリン―アムジエン・インコーポレーテツド 化学修飾顆粒球コロニー刺激因子
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
SG47447A1 (en) 1990-06-15 1998-04-17 Univ Yale Compositions and methods for the prevention and diagnosis of lyme disease
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
EP0786521A1 (en) 1991-02-15 1997-07-30 Uab Research Foundation Nucleic acid encoding PspA
US6676942B1 (en) 1991-08-15 2004-01-13 Smithkline Beecham Biologicals (S.A.) Osp a proteins of Borrelia burgdorferi subgroups, encoding genes and vaccines
DK0598816T3 (da) 1991-08-15 1999-11-22 Deutsches Krebsforsch Osp A-proteiner fra Borrelia Burgdorferi-undergrupper, hvilke proteiner koder for gener og vacciner
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
US6248562B1 (en) 1993-11-01 2001-06-19 Research Foundation State University Of New York Chimeric proteins comprising borrelia polypeptides and uses therefor
US7008625B2 (en) 1993-11-01 2006-03-07 Research Foundation Of The State University Of New York Recombinant constructs of Borrelia burgdorferi
WO2002016422A2 (en) * 2000-08-18 2002-02-28 Research Foundation Of The State University Of New York Recombinant constructs of borrelia burgdorferi
PT726955E (pt) * 1993-11-01 2004-08-31 Brookhaven Science Ass Llc Proteinas quimericas compreendendo polipeptidos borrelia: suas utilizacoes
DE69716240T2 (de) 1996-02-12 2003-06-26 Ml Lab Plc London Neue methode zur impfung sowie impfstoffe dafür, die eine epitopkodierende nukleinsäure und ein epitopenthaltende peptid beinhalten
US6368603B1 (en) * 1997-03-05 2002-04-09 Merial Limited Lyme combination compositions and uses
EP1012181B1 (en) * 1997-06-30 2006-08-23 The Administrators Of The Tulane Educational Fund Surface antigens and proteins useful in compositions for the diagnosis and prevention of lyme disease
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
GB9726555D0 (en) 1997-12-16 1998-02-11 Smithkline Beecham Plc Vaccine
US6541011B2 (en) * 1998-02-11 2003-04-01 Maxygen, Inc. Antigen library immunization
GB9811219D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel process
PT1311540E (pt) * 2000-08-18 2008-03-20 Univ New York State Res Found Ospa de borrelia burgdorferi modificada
EP1939294A1 (en) * 2000-08-18 2008-07-02 Research Foundation Of State University Of New York Recombinant constructs of borrelia burgdorferi
EP1613641B1 (en) 2003-04-02 2009-01-14 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cholesterol-containing compounds and their use as immunogens against borrelia burgdorferi
KR20060019515A (ko) * 2003-04-16 2006-03-03 와이어쓰 홀딩스 코포레이션 수막구균 질환의 예방 및 치료용 신규 면역원성 조성물
DE602005020913D1 (de) * 2004-03-24 2010-06-10 Merck Sharp & Dohme Optimierte expression von hpv-52-l1 in hefe
WO2006014292A2 (en) 2004-07-02 2006-02-09 Dattwyler Raymond J Oral vaccine for borrelia
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
WO2007065098A2 (en) 2005-11-29 2007-06-07 Virginia Commonwealth University Polyvalent chimeric ospc vaccinogen and diagnostic antigen
RU2008126239A (ru) * 2005-11-29 2010-01-10 Вирджиния Коммонвелт Юниверсити (Us) Поливалентный химерный вакциноген и диагностический антиген ospc
CA2661224A1 (en) 2006-09-15 2008-03-20 Intercell Ag Borrelia antigens
AU2008217189B2 (en) 2007-02-22 2013-06-13 Baxalta GmbH Method of purification of hydrophobic proteins
MX2009013949A (es) * 2007-06-26 2010-05-24 Glaxosmithkline Biolog Sa Vacuna que comprende conjugados de polisacárido capsular de streptococcus pneumoniae.
US8835620B2 (en) * 2008-01-11 2014-09-16 Vgx Pharmaceuticals, Llc Vaccines against multiple subtypes of dengue virus
EP2274616A1 (en) 2008-04-22 2011-01-19 The Research Foundation of State University of New York Borrelia burgdorferi cell envelope protein array
EP2283031B1 (en) 2008-05-02 2017-04-12 Virginia Commonwealth University Lyme disease vaccine
CN107641151B (zh) 2010-05-14 2021-10-01 百深公司 Ospa嵌合体及其在疫苗中的用途
RU2015106742A (ru) * 2012-07-27 2016-09-20 Бакстер Интернэшнл Инк. Композиции, содержащие химерные молекулы ospa и способы их применения

Also Published As

Publication number Publication date
MX2012013264A (es) 2014-12-05
KR20200084062A (ko) 2020-07-09
CN103118701A (zh) 2013-05-22
KR102085465B1 (ko) 2020-03-05
US20140141030A1 (en) 2014-05-22
EP3650041A1 (en) 2020-05-13
CA2798331A1 (en) 2011-11-17
KR20180082633A (ko) 2018-07-18
JP6030052B2 (ja) 2016-11-24
RU2012153752A (ru) 2014-06-20
MX2012013261A (es) 2013-04-19
US8623375B2 (en) 2014-01-07
CN103108652A (zh) 2013-05-15
AU2011252850A1 (en) 2012-11-29
PL2569008T3 (pl) 2021-04-19
SI2569009T1 (sl) 2020-02-28
US20110293652A1 (en) 2011-12-01
MX375965B (es) 2025-03-07
AU2011252844A1 (en) 2012-11-29
EP3705133A3 (en) 2021-01-06
US20120020973A1 (en) 2012-01-26
US8623376B2 (en) 2014-01-07
US9334311B2 (en) 2016-05-10
US9303073B2 (en) 2016-04-05
US9895434B2 (en) 2018-02-20
KR20130133120A (ko) 2013-12-06
KR102130584B1 (ko) 2020-07-07
EP2569009A1 (en) 2013-03-20
JP2016168057A (ja) 2016-09-23
JP6227407B2 (ja) 2017-11-08
MX348113B (es) 2017-05-29
CN107641151A (zh) 2018-01-30
BR112012027315A2 (pt) 2016-11-16
CA2799181A1 (en) 2011-11-17
KR20200024354A (ko) 2020-03-06
EP2569008B1 (en) 2019-12-25
BR112012027315B1 (pt) 2021-08-17
BR112012027315A8 (pt) 2020-09-01
KR20190027955A (ko) 2019-03-15
KR20130062954A (ko) 2013-06-13
CA2799181C (en) 2023-10-24
AU2011252844B2 (en) 2014-07-03
US20140141029A1 (en) 2014-05-22
BR112012029058A2 (pt) 2020-06-23
WO2011143623A1 (en) 2011-11-17
CN107641151B (zh) 2021-10-01
KR20180031814A (ko) 2018-03-28
RU2583289C2 (ru) 2016-05-10
US20160235830A1 (en) 2016-08-18
JP2018150386A (ja) 2018-09-27
JP2013529077A (ja) 2013-07-18
AU2011252850B2 (en) 2016-03-17
JP2016171816A (ja) 2016-09-29
CN103118701B (zh) 2017-10-24
CN103108652B (zh) 2016-05-11
EP2569009B1 (en) 2019-10-09
CA2798331C (en) 2022-03-15
KR102222869B1 (ko) 2021-03-04
RU2017138652A (ru) 2019-02-11
JP2020178719A (ja) 2020-11-05
MX340739B (es) 2016-07-22
EP3705133A2 (en) 2020-09-09
RU2012153972A (ru) 2014-06-20
JP6965417B2 (ja) 2021-11-10
SI2569008T1 (sl) 2020-02-28
BR112012029058B1 (pt) 2022-03-29
KR102230562B1 (ko) 2021-03-22
US20180296656A1 (en) 2018-10-18
RU2017138652A3 (pl) 2021-03-15
JP2013529078A (ja) 2013-07-18
WO2011143617A1 (en) 2011-11-17
EP3705133B1 (en) 2024-06-26
US11305000B2 (en) 2022-04-19
EP2569008A1 (en) 2013-03-20
RU2636455C2 (ru) 2017-11-23

Similar Documents

Publication Publication Date Title
PL2569009T3 (pl) Chimery ospa i ich zastosowanie do szczepień
IL249669A0 (en) Converted 5-fluoro-1h-pyrazolopyridines and their use
PT2539326T (pt) Ariltriazolonas ligadas a bisaril e sua utilização
ZA201305076B (en) Substituted 1-benzylccloalkycarboxlic acids and use thereof
ZA201208173B (en) Peptices and their use
IL215389A0 (en) Pneumococcal vaccine and uses thereof
SI2606120T1 (sl) Človeške facilitacijske celice in njihova uporaba
ZA201300930B (en) St-246 liquid formulations and methods
ZA201302168B (en) Electrode unit for use in a fryer and fryer comprising a said electrode unit
PL2521445T3 (pl) Preparat i jego zastosowanie
ZA201304235B (en) Oprf/i agents and their use in hospitalized and other patients
PL2552440T3 (pl) Nowa kombinacja i zastosowanie
PT2563806E (pt) Leucolectinas humanas e suas utilizações
GB201006479D0 (en) Garment and use thereof
GB201008286D0 (en) Device and use
GB201005441D0 (en) Improvements in wheelchairs
ZA201206667B (en) Improvements in and relating to implements
GB201001170D0 (en) Novel peptides and their use in therepy and diagnosis
GB201021105D0 (en) Improvements in and relating to parathas
TWM402679U (en) Portable pillow
GB201022018D0 (en) Improvements in fluid collection devices